Anavex Life Sciences (AVXL) Stock Forecast & Price Target

$12.56 +1.69 (+15.55%)

(As of 12/26/2024 05:45 PM ET)

Anavex Life Sciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 3 Analyst Ratings

Sell
0

Hold
0

Buy
3

Based on 3 Wall Street analysts who have issued ratings for Anavex Life Sciences in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 2 have given a buy rating, and 1 has given a strong buy rating for AVXL.

Consensus Price Target

$44.00
250.32% Upside

According to the 3 analysts' twelve-month price targets for Anavex Life Sciences, the average price target is $44.00. The highest price target for AVXL is $46.00, while the lowest price target for AVXL is $42.00. The average price target represents a forecasted upside of 250.32% from the current price of $12.56.

Get the Latest News and Ratings for AVXL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Anavex Life Sciences and its competitors.

AVXL Analyst Ratings Over Time

Type	Current Forecast 12/28/23 to 12/27/24	1 Month Ago 11/28/23 to 11/27/24	3 Months Ago 9/29/23 to 9/28/24	1 Year Ago 12/28/22 to 12/28/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$44.00	$43.00	$40.00	$41.00
Forecasted Upside	250.32% Upside	376.19% Upside	604.23% Upside	327.08% Upside
Consensus Rating	Buy	Buy	Strong Buy	Buy

Mysterious drone activity triggers massive 1,366% surge (Ad)

If mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But here’s what you really need to know: An early warning signal tipped off investors to a tiny drone stock that later skyrocketed 1,366%.

👉 Click here now to see how this signal works.

AVXL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AVXL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Anavex Life Sciences Stock vs. The Competition

Type	Anavex Life Sciences	Medical Companies	S&P 500
Consensus Rating Score	3.33	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	250.32% Upside	25,769.18% Upside	13.32% Upside
News Sentiment Rating	Positive News See Recent AVXL News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/26/2024	HC Wainwright 2 of 5 stars		Boost Target	Buy ➝ Buy	$40.00 ➝ $42.00	+286.38%
12/23/2024	D. Boral Capital 0 of 5 stars		Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00	+433.02%
7/22/2024	EF Hutton Acquisition Co. I 1 of 5 stars	J. Kolbert Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
2/9/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$35.00 ➝ $28.00	+156.18%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:47 AM ET.

AVXL Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Anavex Life Sciences is $44.00, with a high forecast of $46.00 and a low forecast of $42.00.
: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last twelve months. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVXL shares.
: According to analysts, Anavex Life Sciences's stock has a predicted upside of 250.32% based on their 12-month stock forecasts.
: Anavex Life Sciences has been rated by research analysts at D. Boral Capital, and HC Wainwright in the past 90 days.
: Analysts like Anavex Life Sciences more than other "medical" companies. The consensus rating for Anavex Life Sciences is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AVXL compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

[PDF] The Opportunity in Gold (Ad)

Commodities expert, Geof Smith, insists that the supercycle on gold is just getting warmed up. In fact, even though gold looks like this since he initially called a major bull run 11 months ago… He’s still predicting it will be the TOP trade of 2025. His free eBook explains why You see, the last time gold launched into a supercycle like this it surged 536% The time before that was over 1,000%... That’s why Geof released this urgent guide to help you. Most people think they’ve missed out, but he thinks we’re at the very beginning of what could be the largest gold rally of our lifetimes. But, believe it or not, Geof doesn’t think you should just buy and hold precious metals. He’ll share more about his approach inside the eBook and it might surprise you.

Tap here to read it

This page (NASDAQ:AVXL) was last updated on 12/27/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anavex Life Sciences (AVXL) Stock Forecast & Price Target